Genomic Structure and Genetic Mapping of the Human Neutral Cysteine Protease Bleomycin Hydrolase'
Total Page:16
File Type:pdf, Size:1020Kb
(CANCER RESEARCH57. 4191—4195,October1, 1997] Advances in Brief Genomic Structure and Genetic Mapping of the Human Neutral Cysteine Protease Bleomycin Hydrolase' Susana E. Montoya, Robert E. Ferrell, and John S. Lazo2 Departments ofHuman Genetics [S. E. M., R. E. F.J and Pharmacology [J. S. LI, University of Pittsburgh, Pittsburgh. Pennsylvania 1526/ Abstract reported to bind DNA and to act as a repressor of the Gal4 regulatory system (10). Thus, BH, which has been conserved during evolution, is Bleomycin hydrolase (BH) is the only known eukaryotic enzyme that likely to have important physiological functions in human cells in inactivates the widely used antineoplastic agent bleomycin (BLM) and is a cluding its key role in drug metabolism. We now report the genetic primary candidate gene for protection against lethal BLM-induced pul monary fibrosis and for BLM resistance in tumors. Human B!! was found mapping of the human BH gene and its overall genomic organization, to exist as a single gene that was mapped to chromosome 17 using National which corroborates membership in the cysteine protease superfamily. Institute of General Medical Sciences human/rodent hybrid mapping panels and localized to 17q11.1—11.2 by linkage analysis using the Centre Materials and Methods d'Etude du Polymorphisme Humain reference database. The human BH gene consisted of 11 exons ranging in size from 69—198bpseparated by Characterization of Human BH Genomic Structure. Amplification introns ofapproximately 1kb, reflectingthe archetypal genomicstructure primers (Fig. 1) from adjacent exons were designed using the human cDNA of the cysteine protease family. A polymorphic site was identified in the sequence (8) and intron-exon boundary data from the 5' end of the mouse BH eleventh exon at bp 1450 encodIng either valine or Isoleucine. These gene.4 Intronic regions were amplified from human genomic DNA using fmdings provide essential tools requlred to define the role of RH in long-distance PCR (Elongase; Life Technologies, Inc., Gaithersburg, MD) and BLM-induced pulmonary fibrosis and BLM resistance in tumors. sized on ethidium bromide-stained 1% agarose gel with a 1-kb ladder molec ular size marker (Life Technologies, Inc.). Confirmation of the identity of the Introduction PCR products and determination of intron-exon boundaries were performed by dye-labeled terminator direct cycle sequencing of the PCR products (1 I ) using BLM3 is an essential component of combination chemotherapy the DNA sequencing kit (Applied Biosystems, Foster, CA). Sequencing prod regimens (1, 2). Despite the importance of BLM for curative thera ucts were analyzed on an ABI Prism 377 automatic DNA sequencer (Applied pies, low doses of BLM induce pulmonary toxicity in approximately Biosystems) and assembled using sequencer v.3.0 (Gene Codes Corp., Ann 3—5%of patients, and cumulative doses greater than 450 mg induce Arbor, MI). The intron-exon boundary between intron 6 and exon 6 was potentially lethal pulmonary toxicity in up to 10% of patients (1). The determined from the homologous region of the cloned mouse gene.4 molecular basis for this untoward effect is not established, and accu Chromosomal Mapping of the Human BH Gene. Preliminary localiza rate methods to screen patients for sensitivity before treatment are tion of the human BH gene was obtained using PCR-based analysis of NIGMS unavailable. Recent studies indicate a genetic basis for susceptibility monoclonal hybrid mapping panel 2 (Coriell Institute for Medical Research, Camden, NJ) with primers BHB11 and BHB12 described in Fig. 1. Amplifi to BLM-induced pulmonary fibrosis (3). BH is the only known cation was performed in a DNA thermal cycler 480 (Perkin-Elmer Corp., eukaryotic enzyme that can inactivate BLM (1), and there is consid Foster City, CA) in a final volume of 25 @lcontaining 500 ng of genomic erable evidence that BH can protect pulmonary tissue from BLM DNA, 0.5 unit of Taq polymerase (Life Technologies, Inc.), I.5 mMMgCI2, induced lung injury (1, 4). Deletion of BH in yeast cells results in 200 @.LMeachdeoxynucleotide triphosphate, 240 flM each primer, and 7% increased sensitivity to BLM (5), and expression of yeast BH in DMSO. Thermal cycling comprised 30 cycles of 1-mm denaturation at 94°C, mammalian cells results in resistance to BLM (6). Mammalian BH has 30-s annealing at 58°C,and 1-mm extension at 72°C.Results from monoclonal been purified to homogeneity, and its substrate specificity, inhibitor hybrid mapping panel 2 were confirmed by analysis of NIOMS human/rodent sensitivity, and deduced catalytic domains suggest its membership in hybrid mapping panel I (Coriell Institute for Medical Research). Panel I was the cysteine protease superfamily that includes the calpains, cathep probed with the BHB11IBHBI2 primer pair as well as a second primer pair sins, and the prototype, papain (7). Human BH cDNA encodes a comprised of BHB11 and BHCI2 using long-distance PCR (Elongase; Life 455-amino acid polypeptide that is highly conserved among species Technologies, Inc.). Regional localization of the BH gene was performed using the NIGMS chromosome 17 regional mapping panel (Coriell Institute for with 40% identity to the yeast BH homologue Gal6 (8). Human BH is Medical Research). expressed in many tissues with elevated expression levels found in the Genetic Mapping of Human BH. Based on the report of a possible testis, skeletal muscle, and pancreas and low expression levels seen in polymorphism at bp 1450 (8), exon 1 1 was amplified for SSCP analysis using the colon and peripheral blood leukocytes (8). Based on crystal primers BHZ11 and BHZI2 (Fig. 1) with the same reaction conditions as structure analysis, yeast BH is characterized as a homohexamer that described for primers BHB1 1 and BHB12. The PCR products were screened resembles a 205 proteasome with a prominent central channel housing by a modified SSCP analysis (12) using 4—20%Tris-borateEDTA precast gels the conserved cysteine protease active sites (9). Yeast BH is also (Novex, San Diego, CA) run on a vertical electrophoresis unit (Mighty Small II Vertical Electrophoresis Unit; Hoefer, San Francisco, CA) for 2.5 h with at Received 7/24/97; accepted 8/14/97. 20 mA witha temperaturegradientof —7°C—20°C(ProgrammableTempera The costs of publication of this article were defrayed in part by the payment of page ture Controller; Polyscience, Niles, IL). Gels were visualized by staining with charges. This article must therefore be hereby marked advertisement in accordance with SYBR Green II (Molecular Probes, Eugene, OR) for 20 mm followed by 18 U.S.C. Section 1734 solely to indicate this fact. inspection using the still video imaging system (Eagle Eye II; Stratagene, La I Supported in part by NIH Grant CA43917 and the Fiske Drug Discovery Fund. Jolla, CA). Confirmation of the A14500 polymorphism and genotyping was 2 To whom requests for reprints should be addressed, at Department of Pharmacology. E-1340 Biomedical Science Tower, University of Pittsburgh, Pittsburgh, PA 15261. performed by direct cycle sequencing of the PCR products. The human BH 3 The abbreviations used are: BLM, bleomycin; BH, bleomycin hydrolase; SSCP, gene was genetically mapped by linkage analysis using the 10 informative single-strand conformational polymorphism; MOMS, National Institute of General Mcd ical Sciences; ABI, Applied Biosystems Incorporated; CHLC, Cooperative Human Link age Center; LOD, log of odds; CEPH, Centre d'Etude du Polymorphisme Humain. 4 T. P. G. Calmels, D. R. Schwartz, and J. S. Lazo, unpublished observations. 4191 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 1997 American Association for Cancer Research. BH GENE GGCGCCATGAGCAGCTCGG . cctgtttggtctcccaacagGACTGAATI@CGGAGAA BHAII(+.I) BHBII(+,2) GGTAGCFGCFCTGATACAGAAA@TGAATTCCGACCCCCAGTTCGTACTTG CCCAGAATGTCGGGACCACCCACGACCTGCTGGACATCTGTCTGAAGCG GGCCACGGTGCAGCGCGCGCAGCATGTGTTCCAGCACGCCGTGCCCCAG GAGGGCAAGCCAATCACCAACCAGAAGAGCTCAGgtgtgggctgccacttctcc gat SHBI2(-. 1) gtgctttcttgUtcaGGCGATGCTGGATCTITrCTrGTcTGAATGrrATGAGGCTF BHCtI(+.3) CCATTCATGAAAAAGTrAAATATTGAAGAA1TrGAGTrrAGCCAATC@TA BHCI2(-, 2) QQlGmTTTTGGGACAAGgtatgggacagatctggcaa taacffictttactctttagGTl'GAAC GCTGTTATTTCTfCTTGAGTGCTrTTGTGGACACAGCCCAGAGAAAGGAG B}tDII(+.4) CCTGAGGATGGGAGGCTGGTGCAGTI'iriGCI'TATGAACCCTGCAAATG BHDI2(-. 3) ATGGTGGCCAATGGGATATGC1°I'GTFAATATFGTTGgtaaaagftctttctttaat tag aatttgttItcttttagAAAAATATGGTGTTATCCCTAAGAAATGCTfCCCTGAATCTT BHEII(+. 5) 514E12(-. 4) AIAQAACAGAGGCAACCAGAAGGATGAATGATATFCTGAATCACAAGgtaC aatatatgaagcaggg tgaataagmctgtcatagATGAGAGAATTCTGTATACGACTGCGA ACCTGGTACACAGTGGAGCA4CGAAAGGAGAAATCrCGGCCACACAGGA BHFI2(-. 5) CGTCATGATGGAGGAG ATATrCCGAGTGGTGTGCATCTGTTTGGGTAA BHGII(+.6) Fig. 1. Intron-exon boundaries of the human BH gene. Exons are I@ACCAGAGACATTCACCTGGGAATATCGAGACAAAGATAAAAA1°FATC indicated in bold uppercase letters. Fully conserved consensus sequences next to the primer name indicates forward (+) or reverse (—)primer. Primer pairing is indicated by a number in parentheses next to primer CCACTCTTCAATATGGAAGATAAGgttgggaatggcactgga tacttaacaatgtggctgtagt name, e.g.. BHAI l(+ ,l) and BHB12(—1)form primer pair I. acttagcttgtaggcagagatgatgagcttgatggaaacatgaacctagaggagagctgtgtgttgcttgacattcctggttttgt gccctaattaatgtgUcttgatcftgatagATTTGTTTAGTGAATGACCCTAGGCCCCAGCAC AAGTACAACAAACrflACACAGTGGAATAcTTAAGCAATATGGTrGGTGG BHHI2(-. 6) GAGAAAAACTCTATACAACAACCAGCCCArfGAcrrCcrG@t@GATGG BHH1I(+. 7) TTGCTGCCTCCATCAAAGATGGAGAGgttggtaftgtttctgtattttgcacauggggttaaaacatct tttacttctttggtataataggaaaatggggtttatgttgacutcttcctctttcttctgtttctagGCTGTGTGQmG